Glyburide and pharmacologically related chemicals may be used to protect cells and organisms, including humans, against the harmful effects caused by exposure to ionizing radiation

About

Technology: The inventors have discovered a novel application of a clinically used drug, namely the second-generation sulfonylurea glyburide as a protectant against lethal ionizing radiation. Glyburide and pharmacologically related chemicals may be used to protect cells and organisms, including humans, against the harmful effects caused by exposure to ionizing radiation from therapeutic, accidental or terroristic use.    Applications: * Valuable for firefighter, police, workers or soldiers that must enter areas, which are heavily contaminated with radiation.  * Protection against untoward radiation toxicity that occurs after therapeutic doses of radiation.  * Useful for astronauts, who will be exposed to radiation due to space travel.    Advantages: * Inexpensive compound and concept to develop, as glyburide is already available from multiple sources.    Provisional Patent Application filed   Background: The identification and development of effective radioprotectors and mitigators is of considerable importance because of the common application of ionizing radiation (IR) in medical practice, possible accidental exposure to radiation and potential exploitation of radiation by terrorists. Unfortunately, currently there are no approved drugs to prevent acute radiation syndrome, despite extensive exploration.  

Register for free for full unlimited access to all innovation profiles on LEO

  • Discover articles from some of the world’s brightest minds, or share your thoughts and add one yourself
  • Connect with like-minded individuals and forge valuable relationships and collaboration partners
  • Innovate together, promote your expertise, or showcase your innovations